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Abstract
The clinical entity of pauci-immune vasculitis encompasses a group of diseases that may 
involve any organ system of the body and may be fatal if left untreated. This chapter 
will review these diseases, with a special interest in the clinical setting of kidney involve-
ment. Small vessel vasculitides associated with the presence of antineutrophil cytoplas-
mic autoantibodies in the circulation will be the main part, since the vast majority of 
patients with histopathological proof of pauci-immune vasculitis are positive for these 
antibodies. Pauci-immune glomerulonephritis often manifests with rapidly deteriorating 
kidney function, while it may be accompanied by systemic necrotizing small vessel vas-
culitis such as microscopic polyangiitis, granulomatosis with polyangiitis, or eosinophilic 
granulomatosis with polyangiitis. Importantly, antineutrophil cytoplasmic autoantibody 
specificity has been shown to be associated with distinct clinical syndromes and different 
prognostic profiles among patients with pauci-immune vasculitis allowing easier rec-
ognition of the disease and long-term prognosis. Each of the clinical phenotypes will be 
described thoroughly with respect to the criteria required for establishment of diagnosis, 
the specific characteristics of renal and extrarenal histopathology, the clinical picture, the 
therapeutic management, and prognosis in short and long terms.
Keywords: pauci-immune, vasculitis, kidney involvement, rapidly progressive 
glomerulonephritis
1. Introduction
The principal characteristic of pauci-immune vasculitides is the paucity of staining for immu-
noglobulins in immunofluorescence, while they may occur as a renal-limited disease or as 
a component of systemic disease, i.e., necrotizing small vessel vasculitis [1, 2]. They affect 
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small- and medium-sized vessels, and they represent the most common cause of crescentic 
glomerulonephritis, i.e., glomerulonephritis with 50% or more glomeruli being involved with 
crescents. The systemic vasculitides that may be accompanied by pauci-immune crescentic 
glomerulonephritis include three major clinical phenotypes: microscopic polyangiitis (MPA), 
granulomatosis with polyangiitis (GPA), and eosinophilic granulomatosis with polyangiitis 
(EGPA) [2]. An extremely big proportion (85–90%) of the patients with active untreated pauci-
immune crescentic glomerulonephritis and vasculitis are positive for antineutrophil cyto-
plasmic antibodies (ANCA) [1], and therefore, the clinical entity is called ANCA-associated 
vasculitis. Distinct clinical syndromes and disease profiles have been associated with the type 
of ANCA. The classification of these diseases has been standardized by the Chapel Hill vascu-
litis nomenclature consensus conference in 1994 and revised in 2012. According to the current 
classification [3, 4] system for small vessel vasculitides, diagnostic definitions of ANCA-
associated vasculitides include EGPA, which is characterized by the presence of asthma and 
eosinophilia, and necrotizing granulomatous inflammation is present [5], MPA is charac-
terized by systemic necrotizing small vessel vasculitis with no evidence of granulomatous 
inflammation or asthma [5] and finally GPA if there is histopathological proof of necrotizing 
granulomatous inflammation or a clinical equivalent of it in any tissue. Moreover, patients 
with GPA are usually positive for C-ANCA (PR3-ANCA), patients with MPA are slightly 
more often positive for P-ANCA (MPO-ANCA), and patients with EGPA and renal-limited 
ANCA small vessel vasculitis have predominantly P-ANCA (MPO-ANCA) [1]. In some 
patients with pauci-immune vasculitis, conventional serologic assays fail to detect ANCA, 
although they present with the classic clinical and pathological characteristics of the disease. 
In this regard, recent advances in the field have shown that MPO-ANCA may react against a 
sole linear sequence in this group of patients [6].
This chapter will focus in pauci-immune vasculitides with kidney involvement, including 
the description of histopathological characteristics of renal and extrarenal lesions, epidemi-
ology, pathogenesis, spectrum of clinical manifestations, definitions and diagnostic criteria 
of treatment response, and long-term outcomes. In addition, the current therapeutic options 
and prognostic factors resulting from recent advances in the understanding of correlations 
between laboratory and serological and clinical parameters will be reviewed.
2. Epidemiology
The incidence of pauci-immune glomerulonephritis has been shown to be higher in older 
patients, while distribution between genders appears equal [7–9]. In the United States specifi-
cally, it has been estimated in 3.1 cases/million/year, with the disease being significantly more 
frequent in Caucasians, males, and individuals older than 65 years, while 95% of cases were 
found ANCA positive at diagnosis [7, 10]. In Europe, the incidence has been reported is 1–2 
cases in 100,000 [9, 11], with an increasing trend in recent years up to 2000 [12]. A potential 
explanation may be the increased awareness of these diseases among physicians and also 
the easier recognition of them after the introduction of ANCA testing. However, since the 
incidence has been shown relatively unchanged since the early 2000s, it is most probable that 
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the increased physician awareness, following the introduction of ANCA testing in routine 
clinical practice, is the most possible reason [13]. Additionally, the incidence of GPA is higher 
than that of MPA in northern Europe, while MPA is predominant among cases of ANCA-
associated vasculitis in southern Europe [13–15].
Likewise, the prevalence of ANCA-associated small vessel vasculitis has been estimated in 
46–184 cases/million [13], with the rate increasing during the last two decades. Patient sur-
vival has been improved significantly during this period, as the treatment options are more 
effective and physicians are aware of the disease.
3. Genetic background
Genetic predisposition appears to play a critical role in ANCA vasculitis, as shown from sev-
eral reports. A study in a multiethnic cohort of patients from the University of North Carolina 
at Chapel Hill (USA) showed that GPA is quite infrequent among African Americans [16] with 
the HLA-DRB1*15 allele being a risk factor for PR3-ANCA disease in this population [16]. It is 
probable that there is a variation of the HLA-DRB1*15 allele worldwide, which is also recog-
nized in the variation of clinical phenotypes of the disease across different geographical areas. 
Furthermore, the overall incidence rate of ANCA disease was similar between Japan and 
Europe; GPA and PR3-ANCA vasculitis were shown to be much less common in Japan [13].
4. ANCA role in pathogenesis
ANCA are antibodies which are directed against proteins in the cytoplasmic granules of 
neutrophils and the lysosomes of monocytes. They were first reported by Dr. D. Davies in 
1982 [17] and were subsequently correlated with Wegener’s granulomatosis and microscopic 
polyangiitis [18, 19]. However, in 1988, it was shown that most of the patients with pauci-
immune crescentic glomerulonephritis have ANCA in their circulation, irrespective of the 
coexistence or not of systemic vasculitis [8]. ANCA have been distinguished on the basis of 
indirect immunofluorescence microscopy; cytoplasmic, C-ANCA, or perinuclear, P-ANCA, 
depending on the given pattern, and by enzyme immunoassay; and anti-myeloperoxidase 
(MPO-ANCA) and anti-proteinase 3 (PR3-ANCA) depending on the antigen protein. More 
than 95% of cytoplasmic ANCA are PR3-ANCA, and more than 95% of perinuclear ANCA are 
MPO-ANCA. ANCA glomerulonephritis occurs as a renal-limited disease or as a component 
of systemic necrotizing small vessel vasculitis [8, 19, 20].
After the discovery of ANCA, great effort has been made in understanding the etiology and 
pathogenesis of these diseases in order to discover new therapies. A pathogenic role of ANCA 
has been demonstrated by clinical observations and experimental studies, i.e., in vitro stud-
ies, which reveal that both PR3 and MPO-ANCA IgG activate neutrophils that then release 
mediators of acute inflammation [21–24]. Accordingly, it has been found that neutrophils acti-
vated by ANCA IgG can kill cultured endothelial cells in some occasions while activation of 
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neutrophils by ANCA causes integrin and cytokine receptor-mediated adherence to cultured 
endothelial cells and transmigration across the endothelial layer [1, 25] and conformational 
changes in β integrins, enhancing ligand binding. Furthermore, unregulated adhesion mol-
ecules in glomerular lesions, coming from kidney biopsy specimens of patients with ANCA-
associated vasculitis, support the interaction of ANCA-activated neutrophils with vessels [26].
However, the most significant evidence that ANCA are involved in the pathogenesis of these 
diseases are provided by in vivo studies and specifically by a mouse model in which passive 
transfer of anti-MPO IgG (MPO-ANCA) or anti-MPO lymphocytes resulted in induction of glo-
merulonephritis. Xiao et al. developed a model in which intravenous administration of anti-MPO 
IgG into either immunocompetent mice, or Rag2−/− mice that have no functioning T or B cells, 
causes pauci-immune crescentic glomerulonephritis and small vessel vasculitis, remarkably 
similar to human disease. Within a period of 6 days after the injection, all mice developed glo-
merulonephritis identical with the human one, while some of them developed manifestations of 
systemic vasculitis, with leukocytoclastic angiitis, necrotizing arteritis, lung capillaritis, and nec-
rotizing granulomatosis inflammation [1, 27–30]. Likewise, severe crescentic glomerulonephritis 
with systemic vasculitis can be caused by passive transfer of splenocytes from MPO−/− mice 
that have been immunized with murine MPO. The renal injury in this model is exacerbated by 
stimulation with LPS [29] and appears dependent on an intact alternative complement pathway 
and the presence of neutrophils [31]. Another model produced focal segmental pauci-immune 
glomerulonephritis and focal pulmonary capillaritis in rats by immunization with human MPO, 
which induced anti-MPO antibodies that cross react with human and rat MPO [32].
Importantly, there are patients who carry a clear clinical and histopathological diagnosis of 
pauci-immune necrotizing and crescentic glomerulonephritis and vasculitis, in whom negative 
tests for ANCA are coming out repetitively. This might lead to significant delays in establish-
ing the correct diagnosis and initiating appropriate immunosuppressive treatment. Exploring 
this issue, a multicenter study recently reported the development of a novel assay to identify 
specific target epitopes for ANCA [6], a methodology, which led to the detection of MPO-
ANCA in patients with ANCA-negative disease that reacted against a sole linear sequence. 
Autoantibodies against this specific epitope had certain pathogenic properties, as demonstrated 
by their capacity to activate neutrophils in vitro and to induce nephritis in mice. Interestingly, 
the researchers detected a fragment of ceruloplasmin in serum, which was eliminated in puri-
fied IgG, allowing detection of ANCA subsequently. Besides, patients with ANCA-negative 
small vessel vasculitis were found to have a restricted autoantibody response against the linear 
epitope on MPO (aa 447–459), which is the same one that was found to be associated with 
active disease in the MPO-ANCA-positive patients group and declined upon clinical remission 
[6]. The authors concluded that that epitope specificity defines pathogenicity [6].
5. Vasculitic manifestations and ANCA specificity
The antigen against which ANCA is directed, i.e., ANCA specificity, has been shown to be 
strongly associated with the clinical manifestations of the disease, including the affected organ 
systems and the histopathological findings, in patients with pauci-immune vasculitis. In this 
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regard, patients with renal-limited disease, or any form of vasculitis without any radiological 
or histological proof of granulomas, have been shown more likely to have MPO-ANCA, while 
those with necrotizing granulomatous inflammation were shown to have a higher probability 
to have PR3-ANCA. This was captured in a study of 523 patients with biopsy-proven ANCA 
small vessel vasculitis, where the vast majority of patients with renal-limited disease had 
MPO-ANCA (81%), while almost all patients with bone destruction or saddle nose deformity 
had PR3-ANCA (94%) [33]. The relationship between PR3- or MPO-ANCA and the anatomic 
site of the vasculitic manifestation and/or the presence of granulomatous inflammation has 
been shown remarkable. When vasculitis is expanding from the renal parenchyma to the 
gastrointestinal or respiratory tract, MPO-ANCA is found less frequent, while PR3-ANCA 
constantly increases. In patients with histological proof of granuloma at any site, 79% were 
shown to have PR3-ANCA, and 21% were shown to have MPO-ANCA. Therefore, MPO- or 
PR3-ANCA are associated with clinically distinct vasculitic syndromes, a principle which is 
proven critical for the classification of ANCA small vessel vasculitis and in clinical practice. 
Importantly, this relationship has been confirmed by a genome-wide association study, which 
showed that the pathogenesis of ANCA small vessel vasculitis has a substantial genetic com-
ponent, with clear genetic distinctions greatly associated with ANCA specificity [34].
6. Diagnosis of pauci-immune glomerulonephritis
Clinical or pathologic evidence of renal disease is seen in approximately 90% of patients with 
MPA, 80% of patients with GPA and 45% of patients with EGPA. Pauci-immune crescentic 
glomerulonephritis is typically associated with ANCA, since 80–90% of pauci-immune cres-
centic glomerulonephritis occurs in ANCA-positive patients [1, 2, 20, 35]. The clinical presen-
tation of patients with pauci-immune glomerulonephritis includes a range of disease activity 
starting from asymptomatic hematuria to rapidly progressive glomerulonephritis. In most 
cases however, clinical presentation is characterized by an elevated serum creatinine in com-
bination with active urine sediment, i.e., demonstrating dysmorphic erythrocyturia with or 
without red blood cell casts and various degrees of proteinuria [36]. Rapidly progressing glo-
merulonephritis is characterized by reduced glomerular filtration rate occurring in a few days 
or weeks which cannot be attributed to other causes of acute kidney injury. A kidney biopsy 
in such occasion reveals, as said earlier, fibrinoid necrosis along with crescent formation in 
more than 50% of the glomeruli [1]. Yet, a significant proportion of patients present with acute 
renal failure requiring dialysis at the time of disease diagnosis.
7. Extrarenal manifestations
Constitutional symptoms often precede or come with the actual onset of the disease and 
include low-grade fever, fatigue, weight loss, myalgias, and arthralgias [5, 37]. The vast 
majority of patients (94%) when asked reported a prodromal “flu-like syndrome” before the 
overt vasculitic syndrome [40]. Beyond this there is a wide range of extrarenal manifestations 
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of vasculitis including involvement of any site of the body, such as the upper airways, the 
lungs, the gastrointestinal tract, the nerves, and the skin.
Disease of the ear, nose, and throat system, in different forms and degrees of severity, is 
present in 90% of patients with GPA [1, 38, 39]. Typical symptoms are nasal crusting and 
obstruction, bloody nasal discharge or epistaxis-related nasal mucosa ulceration, sinus pain 
with associated drainage, otitis media, and hearing loss. In patients with GPA, the vessels 
supplying the cartilage may be affected, and septal perforation may occur, while invading 
granulomas may cause destructive bone disease disrupting the anatomy of such patients. 
Saddle nose deformation due to collapse of the nasal structure and facial paralysis due to 
facial nerve entrapment may be seen, but the most dangerous complication of upper respi-
ratory involvement is the inflammation of the trachea, especially in the subglottic region, 
because it may result in airway stenosis. Subglottic stenosis and destruction in the sinonasal 
anatomy represent characteristic manifestations of GPA. Lung involvement may manifest 
as necrotizing granulomatous inflammation or alveolar capillaritis and is typically demon-
strated on radiographic studies as nodular opacities or alveolar infiltrates. Pulmonary nod-
ules may cavitate, thus making disease management difficult; infections are superimposed. 
Capillaritis, arteritis, and granulomatous inflammation may cause hemoptysis or massive 
pulmonary hemorrhage, life-threatening conditions, which require immediate induction 
therapy. Among patients with biopsy-proven pauci-immune glomerulonephritis, 53% were 
found to have pulmonary involvement manifested as hemoptysis or massive hemorrhage 
which quickly became fatal in 50% of them [1, 37]. Involvement of the skin with palpable 
purpura and nodules occurs in as many as 25% of patients. Other skin lesions include ery-
thematous macular lesions, papules, infarcts, and necrotic ulcers. Vasculitic lesions in the 
mucous membranes manifest as aphthous stomatitis or oral ulceration. Eye involvement 
includes conjunctivitis, episcleritis, blepharitis, keratitis, or acute visual loss or orbital mass. 
Approximately 30% of patients report symptoms of abdominal pain, gastritis, ischemic 
colitis, or pancreatitis due to involvement of the vessels in abdominal organs. Occasional 
infarction of the bowel with viscus perforation and polymicrobial sepsis may result in life-
threatening phenomena. Cranial nerve palsy, sensory peripheral neuropathy, or mononeuri-
tis multiplex may be seen. Peripheral neuropathy caused by vasculitis in epineurial arterioles 
and arteries occurs in approximately 30% of patients. Vessels in the central nervous system 
can also be affected leading to sudden onset of seizures, cerebrovascular events, and cogni-
tive disorders. Besides, deep vein thrombosis may occur, more frequently among patients 
with ANCA-associated vasculitis than the general population or other autoimmune disor-
ders [39–41]. Anti-plasminogen autoantibodies have been identified in patients with PR-3 
ANCA glomerulonephritis, as a result of utilization of a peptide coded by the antisense RNA 
of the PRTN3 gene [41], and have been associated with such thrombotic phenomena.
The clinical phenotype of EGPA probably denotes a somewhat different disease, manifested 
by asthma, eosinophilia, and granulomatous inflammation in the lung. ANCA are positive in 
70% of the patients, most commonly MPO-ANCA [36], and eosinophilia greater than 10% in 
the peripheral blood is found. Coronary arteritis and myocarditis are the main causes of mor-
bidity and mortality, accounting for 50% of deaths. Renal disease is much less frequent and 
less severe in this disease category, while neuropathy and cardiac disease are more common. 
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However, recent advances in EGPA suggest that the majority of patients, who are ANCA 
positive, also have glomerulonephritis, while those lacking ANCA are more likely to have 
cardiac disease [42].
8. Histopathology
8.1. Renal histopathology
The hallmark histopathologic lesions of acute pauci-immune glomerulonephritis are cres-
cents and fibrinoid necrosis (Figure 1), which are found at the same frequency, irrespective of 
the presence or absence of systemic vasculitis [2, 43]. A wide range of lesions in terms of activ-
ity and severity may be found, ranging from focal segmental fibrinoid necrosis affecting less 
than 10% of glomeruli to severe diffuse necrotizing and crescentic glomerulonephritis that 
may injure all glomeruli (Figure 2). Breaks in Bowman’s capsule are frequent [44]. Another 
element, which may be found, although not disease specific, is periglomerular granuloma-
tous inflammation [1]. ANCA-associated glomerulonephritis is by definition pauci-immune, 
which means that immunofluorescence microscopy reveals no staining or a low level of stain-
ing (less than +2, in the 0–4 scale) (Figure 3) [45]. In a significant number of patients, there 
is evidence for antecedent glomerular or tubulointerstitial injury, manifested by glomerular 
sclerosis, fibrocellular crescents, and interstitial fibrosis. These lesions may be found in dif-
ferent stages of activity or resolution depending on the status of the disease. Nearly 10% of 
biopsy specimens have necrotizing inflammation in small cortical arteries or vascular inflam-
mation of the medullary vasa rectae (Figure 4), causing papillary necrosis if it is severe.
8.2. Extrarenal histopathology
The pathologic features of pauci-immune vasculitic lesions are identical in other organs as 
they are in the kidney. Consequently, leukocytoclastic angiitis affecting vasa recta is very 
Figure 1. Segmental glomerular fibrinoid necrosis with early small cellular crescent formation (H&E 400×).
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similar to that in dermal venules, necrotizing capillaritis in glomeruli is identical to that in 
pulmonary capillaries, and necrotizing arteriolitis and arteritis in renal arteries are histologi-
cally indistinguishable from the necrotizing arteriolitis and arteritis in any site of the body, 
such as perineural arteritis causing peripheral neuropathy, gastrointestinal arteritis leading 
to focal ulceration and hemorrhage, and skeletal muscle arteritis leading to myalgias [1]. The 
histopathological proof of pauci-immune vasculitis prerequisites a paucity of staining for 
immunoglobulins [1] in order to confirm the diagnosis, and thus if glomerulonephritis is not 
present, a tissue biopsy at any site of active disease in any organ should be obtained.
The characteristic histological lesion in the pulmonary system in patients with MPA is 
capillaritis, while among patients with GPA, granulomatous inflammation may be seen as 
well. The necrotizing granulomatous inflammation may involve the upper and/or lower 
Figure 2. Segmental fibrinoid necrosis (red color) in the wall of an artery, associated with inflammation (Masson 200×).
Figure 3. Medullary angiitis in a renal biopsy specimen from a patient with ANCA small vessel vasculitis. Leukocytoclasia 
reminiscent of dermal leukocytoclastic angiitis (H&E 400×).
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respiratory system but may be found in any site, such as in the dermis and subcutaneous tis-
sue. Granulomas are characterized histologically by an irregular central zone of necrosis that 
may have an amphophilic or bluish hue because of finely dispersed nuclear debris [1]. One 
major element of this lesion is epithelioid macrophages which may be numerous, but they do 
not have the compact arrangement seen in other occasions such as sarcoidosis [1]. Over time, 
extensive fibroblastic proliferation is usually seen, which ultimately may evolve into dense 
fibrotic scars. Nevertheless, for any specimen with necrotizing granulomatous inflammation, 
major non-vasculitic differential diagnostic considerations should be made, including myo-
bacterial and fungal infections which need to be ruled out [1]. Conclusively, several sites of 
extrarenal involvement may be used to obtain a tissue biopsy, in order to have histopathologi-
cal proof of the disease. A lung biopsy often requires an open or thoracoscopic lung proce-
dure, while in a small proportion of patients, sufficient tissue for diagnosis can be obtained by 
transbronchial biopsy. Yet, the absence of granulomatous vasculitis on transbronchial speci-
mens should not be considered adequate evidence to exclude the diagnosis of GPA [46]. A 
nasal biopsy is relatively easy and noninvasive, but its diagnostic power is limited by the high 
rate of false-negative results, probably related to the fact that the amount of tissue that can be 
removed is small. A positive lung biopsy is establishing the diagnosis in such cases and from 
one view precludes the need for a kidney biopsy in many cases; however, a renal biopsy is 
still indicated in patients who are diagnosed by lung biopsy, especially if they have severe 
or rapidly progressive renal involvement, in order to assess prognosis and plan immunosup-
pressive therapy in short and long term.
9. Definitions in relation to response to therapy
Diagnosis of active ANCA disease is followed by initiation of immunosuppressive therapy 
with the main goal being induction of remission, defined as stabilization or improvement 
of kidney function, measured by serum creatinine levels, resolution of hematuria, and all 
other organ-specific vasculitic symptoms [36]. However, some patients may not respond 
Figure 4. Negative immunofluorescence in a case of ANCA small vessel vasculitis.
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 sufficiently, a phenomenon which is called “treatment resistance” and characterized by pro-
gressive decline in kidney function with persistent active urine sediment, or persistence or 
new appearance of any extrarenal vasculitic manifestations despite appropriate treatment. 
In addition, there are patients who initially responded to therapy in a manner that let them 
escape life-threatening or advanced organ damage, but it was not feasible for them to achieve 
complete obliteration of the pathogenic process and thus maintained a low grade of persistent 
activity known as “grumbling disease.” Yet, patients achieving remission either complete or 
on therapy may or may not experience one or more disease relapses afterward. These are usu-
ally manifested as vasculitic signs or symptoms in any organ system, although relapses tend 
to affect the same organ systems as on initial presentation, with a new organ involvement 
reported only in 23% of patients [36].
10. Initial treatment
The gold standard of treatment in ANCA-associated vasculitis is the combination of cortico-
steroids with the cytotoxic agent cyclophosphamide [37, 47–50]. Glucocorticoids are given as 
intravenous pulses of methyl-prednisolone (7 mg/kg for 3 consecutive days) followed by oral 
prednisone (1 mg/kg for the first 4 weeks), reduced in a gradual and personalized manner over the 
next 3–5 months [2]. The protocol of treatment with cyclophosphamide in ANCA disease includes 
monthly pulses, given intravenously, starting at a dose of 0.5 g/m2, subsequently increased up 
to 1 g/m2, or orally at an initial dose of 2 mg/kg/day, always adjusted on the patient’s leukocyte 
count. The duration of therapy with cyclophosphamide is usually 6–12 months, depending on 
patient’s initial response [38, 47–51]. Both oral and intravenous schemes of cyclophosphamide 
have been proven equally effective in induction of remission [49], with the cumulative dose 
being significantly lower in the parenteral administration. In terms of achieved remission rates, a 
multivariate analysis showed superior results with the intravenous regimen without significant 
higher relapse rates [49]. Yet, a retrospective study showed [50] that the intravenous scheme of 
cyclophosphamide is associated with a higher risk of relapse, but this was not associated with 
increased rates of end-stage renal disease (ESRD), mortality, or long-term morbidity [50].
More recently, rituximab, a chimeric monoclonal antibody which is directed against the CD20 
antigen of B lymphocytes, has also been used to induce remission in patients with ANCA-
associated vasculitis, either in combination with steroids or cyclophosphamide and steroids 
[52]. A study authored by Jones et al. [52] compared rituximab with cyclophosphamide, as 
inductive therapy in patients with newly diagnosed ANCA-associated vasculitis with renal 
involvement, to a glucocorticoid regimen plus either rituximab with two intravenous cyclo-
phosphamide pulses, or intravenous cyclophosphamide for 3–6 months followed by azathio-
prine. The scheme which contained rituximab, as part of therapy, was not superior to the 
standard one with intravenous cyclophosphamide (76 vs. 82%), with remission rates being 
high in both groups, while the rituximab regimen was not associated with fewer severe 
adverse events in the early phase [52]. Another study, which enrolled 197 ANCA-positive 
patients with either GPA or MPA, compared treatment with rituximab to treatment with 
oral cyclophosphamide for induction of remission. The rituximab-based regimen was shown 
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more efficacious than the cyclophosphamide-based regimen for inducing remission of relaps-
ing disease (67 vs. 42%, p = 0.01). Rituximab was also as effective as cyclophosphamide in the 
treatment of patients with renal or pulmonary involvement [52].
There are two clear indications which justify addition of plasma exchange in the inductive 
phase of treatment in ANCA-associated vasculitis: pulmonary hemorrhage and severe renal 
dysfunction at clinical presentation (serum creatinine is greater than 500 μmol/L). Pulmonary 
hemorrhage, either as isolated capillaritis, or as part of the pulmonary renal syndrome, may 
be a life-threatening condition leading to high mortality rates [1, 53, 54]. A retrospective study 
showed that the prompt institution of plasma exchange in addition to immunosuppressive 
therapy is 100% lifesaving [55] for these patients with diffuse pulmonary hemorrhage due 
to ANCA vasculitis, when compared to 50% historical controls. Furthermore, a randomized 
controlled study of 137 patients within the European Vasculitis Society (EUVAS) group with 
ANCA glomerulonephritis showed a clear benefit with the addition plasmapheresis to stan-
dard treatment in patients with severe renal impairments (serum creatinine >500 μmol/L). 
Specifically, addition of plasmapheresis was associated with a reduction in risk for progres-
sion to ESRD of 24% at 12 months and was also shown to be a positive predictor of dialysis 
independence at 1 year in patients with renal failure [54] (Figure 5).
Aggressive immunosuppressive therapy is warranted in patients with ANCA-associated 
small vessel vasculitis, since patient and renal survival have been shown very poor in 
untreated patients [38]. However, toxicity related to therapy is also problematic. For instance, 
Figure 5. Algorithm to guide initial therapy for patients with newly diagnosed ANCA-associated vasculitis.
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glucocorticoid therapy is associated with osteoporosis, glucose intolerance, and changes in 
body habitus in the long term, while life-threatening infections may occur during the acute 
phase. The frequency of severe infections is higher with the addition of cyclophosphamide. 
Moreover, therapy with cyclophosphamide has been associated with myelosuppression and 
hemorrhagic cystitis which occurs in 10% of patients. Bladder cancer has been estimated in 
5% in 10 years and 16% in 15 years in patients treated with long-term oral cyclophosphamide. 
Myelodysplasia, lymphoma, skin cancer, and gonadal dysfunction are also associated with 
cyclophosphamide therapy [56]. Sufficient hydration and administration of 2-mercaptoeth-
anesulfonate have been used in order to minimize urotoxicity.
Of note, although histopathological diagnosis is always desirable for patients with ANCA dis-
ease, we should underline that immunosuppressive treatment should be started empirically if 
the clinical suspicion for ANCA small vessel vasculitis is high and a tissue diagnosis cannot be 
obtained in a timely manner [18]. This is very important in order to avoid irreversible damage 
since these diseases often follow a rapidly progressive course with devastating consequences 
of the involved tissue.
11. Maintenance of remission
After achievement of remission, the disease course varies substantially among patients with 
ANCA small vessel vasculitis [10, 18]. Occurrence of relapse ranges from 30 to 50%. The major-
ity of patients experience, either sustained long-term remission, or with one or more relapses 
occurring over time. Some patients continue having persistent, low-grade activity [10, 38]. 
Yet, evaluation of outcomes in patients in whom immunosuppressive therapy was discontin-
ued after they attained remission showed similar rates of relapse compared to patients who 
remained on treatment for longer periods [10]. In the light of irreversible side effects related 
to therapy and relapse rates being comparable between long-term treated and not treated 
responders [10], optimal duration of immunosuppressive therapy should be decided on an 
individualized manner. In this regard, maintenance treatment is legitimate for patients who 
have a high rate of relapse, who have had a relapse already, or who maintain some disease 
activity despite full treatment. Undoubtedly, it is a challenge to select those patients in whom 
it is safe to discontinue therapy versus those who require remission maintenance therapy 
[10]. Recently, a prospective randomized trial, which compared two different durations of 
maintenance immunosuppressive therapy for the prevention of relapse in ANCA-associated 
vasculitis [55] showed that prolonged remission maintenance therapy with azathioprine/
prednisolone, beyond 24 months after diagnosis, reduces relapse risk out to 48 months 
and improves renal survival. Nonetheless, the optimum duration of maintenance therapy 
depends on multiple factors. Another randomized controlled trial of patients with PR3-
ANCA disease who remained ANCA positive at the time of stable remission, extending the 
duration of maintenance therapy with azathioprine from 1 year to 4 years (followed by taper), 
was not associated with a significant difference in relapse-free survival at 4 years [35, 57]. 
Finally, these results should not be extrapolated to other agents, especially since the optimal 
duration of maintenance therapy with rituximab has not been formally evaluated. A practi-
cal approach for clinicians is to use predictors of relapse, in order to be able to distinguish 
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those patients who are at increased risk to relapse. Predictors of relapse among responders in 
ANCA-associated vasculitis have been shown to be PR3-ANCA seropositivity [33] and pul-
monary and ear, nose, and throat involvement, each associated with an approximately two-
fold increase in risk for relapse.
In terms of the agents which may be used, for maintenance of remission, conversion from 
cyclophosphamide to azathioprine at a dose of 2 mg/kg/day has been shown to be a safe 
choice with less toxicity [1, 56]. Furthermore, an open-label randomized controlled trial 
which was conducted in 156 patients from 42 European centers found that mycophenolate 
mofetil was less effective than azathioprine for maintaining remission, while adverse event 
rates were not different [56]. Employment of rituximab for the maintenance of remission 
in patients with ANCA vasculitis was tested in a study of 115 patients with GPA, MPA, or 
renal-limited disease after achievement of complete remission with cyclophosphamide and 
glucocorticoid [57]. Patients received either 500 mg of rituximab on days 0 and 14 and at 
months 6, 12, and 18 after study entry or daily azathioprine until month 22. In the rituximab 
group, more patients had sustained remission at month 28 than the azathioprine group, 
while the frequency of severe adverse events was similar between groups [58]. The anti-
microbial agent trimethoprim-sulfamethoxazole has also been proven to prevent relapse 
in patients with GPA, by reducing the episodes of infections, probably by eliminating 
Staphylococcus aureus in the upper airways [59].
12. Management of persistent, refractory, or relapsing disease
Despite available options of treatment, some patients experience persistent symptoms or epi-
sodes of active inflammation that come up repentantly. In this regard, there are some choices 
which have been explored as potential alternatives [60–64] in order to treat the disease and 
minimize toxicity related to cytotoxic therapy in patients with ANCA-associated vasculitis. 
Among them, methotrexate combined with corticosteroids has been shown to lead to remis-
sion in 60–90% [60–62], but it was associated with an elevated rate of relapse [60–62]. Besides, 
yet, the use of methotrexate has been limited to patients with predominantly extrarenal 
manifestations of vasculitis and preserved renal function (serum creatinine <2.5 mg/dl). As 
a result, patients with signs of kidney involvement should not be treated with methotrexate. 
Mycophenolate mofetil is a safe and therapeutically beneficial alternative for patients with 
non-life-threatening, recurrent, or resistant ANCA vasculitis according to the results of a pilot 
study [64]. More recently, there are several reports of refractory disease which has been man-
aged with rituximab, combined with steroids or cyclophosphamide or both, and ended up in 
remarkable improvement [65–67] or even complete remission.
13. Prognosis of patient and renal survival
The most important question of both patients and physicians in the case of ANCA-associated 
vasculitis is the issue of long-term prognosis, especially considering the relapsing and remit-
ting course of this disease in association with the cumulative toxicity of therapy. The relative 
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risk of death has been shown to be almost nine times greater in patients with MPA, who 
presented with lung hemorrhage, and four times greater in patients with cytoplasmic versus 
perinuclear ANCA [67] although the risk of lung hemorrhage was not different from ANCA 
pattern. The use of cyclophosphamide lowered the risk of death nearly six times, compared 
to steroid therapy alone [67]. Accordingly, long-term analysis of patients with GPA, who had 
received treatment with prednisone and cyclophosphamide, revealed that age over 50 years at 
diagnosis and lung or kidney involvement were associated with an almost fourfold increased 
risk for death [67]. The strongest predictors of long-term renal survival were found to be 
entry serum creatinine value, black race, and arterial sclerosis on renal biopsy [67]. Despite 
the certain finding that the higher the entry serum creatinine, the worse the long-term renal 
prognosis, no level of serum creatinine value could be determined beyond which treatment 
was futile, since 50% of the dialysis-dependent patients at onset recovered renal function per-
mitting cessation of dialysis [67]. Taken all together, prompt institution of therapy remains 
the gold standard in these diseases. The risk for progression to ESRD after initial response to 
treatment in patients with ANCA glomerulonephritis was the change in GFR within 4 months 
of treatment. In this regard, after controlling for baseline creatinine level, type of treatment, 
and ANCA specificity, patients with a GFR decrease of 8 ml/min or greater were 5.6 times 
more likely to progress to ESRD than patients with stable GFR [10]. Relapse itself has also 
been shown to increase the probability of progression to ESRD by 4.7 times, with the related 
risk totally attributable to the recurrence of nephritis [10]. In patients with severe renal dys-
function due to ANCA glomerulonephritis, prognostic indicators of GFR after 12 months 
were shown to be age, the percentage of normal glomeruli, tubular atrophy, and intraepi-
thelial infiltrates in the renal biopsy [51], while for those who were dialysis dependent at 
diagnosis, the probability for renal recovery was significantly increased with the addition of 
plasmapheresis [54].
Prediction of treatment resistance has been studied in a large cohort of patients with ANCA-
associated vasculitis [67], recruited by kidney disease, which showed that 23% of the 334 
treated patients became refractory to standard therapy. Most of them ended up to ESRD in 
median of 2 months after initiation of therapy. Female sex, black ethnicity, and severity of 
renal involvement were identified as predictors of treatment resistance. The risk of treatment 
resistance increased 1.28 times for each serum creatinine elevation of 100 μmol/L (1.13 mg/dl). 
Nonetheless, these rates have not been estimated with the newer agents and especially after 
the introduction of rituximab in the treatment of these diseases. Typically, these patients had 
a relapsing and remitting course not recognized by their primary care provider, leading to 
advanced glomerular and interstitial scarring at the time of diagnosis [67].
In conclusion, pauci-immune vasculitides, despite the substantial progress which has been 
achieved in the field of pathogenesis and treatment, remain a group of diseases with sig-
nificant morbidity and mortality, related to the disease itself and the toxicity coming from 
therapy. Renal involvement is one of the most threatening aspects of this disease, espe-
cially considering the side effects related to renal insufficiency and chronic dialysis, in the 
case of extended irreversible damage of the renal tissue. Speed in diagnosis and prompt 
institution of appropriate immunosuppressive treatment endure the key of avoiding such 
outcome.
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